CoChat
Sign Up
Cited by 263

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026

American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi, Echouffo-Tcheugui, Justin B., Everett, Brendan M., Garg, Rajesh, Laffel, Lori M., Lal, Rayhan, Matfin, Glenn, Nelson, Aaron B., Neumiller, Joshua J., Pandya, Naushira, Pekas, Elizabeth J., Peters, Anne L., Pilla, Scott J., Romeo, Giulio R., Rosas, Sylvia E., Sadhu, Archana R., Segal, Alissa R., Simmons, Kimber M., Szmuilowicz, Emily D., ElSayed, Nuha A.·2026·Diabetes Care
DOI 10.2337/dc26-s009
Open this paper in CoChat — free account

Abstract

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee for Diabetes, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc26-s009

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 213

  1. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group, 2016, Mortality in type 1 diabetes in the DCCT/EDIC versus the general population, Diabetes Care, 39, 1378, 10.2337/dc15-2399 · DOI · Paper page
  2. Lachin, 2021, The beneficial effects of earlier versus later implementation of intensive therapy in type 1 diabetes, Diabetes Care, 44, 2225, 10.2337/dc21-1331 · DOI
  3. Lachin, 2021, Understanding metabolic memory: the prolonged influence of glycemia during the Diabetes Control and Complications Trial (DCCT) on future risks of complications during the study of the Epidemiology of Diabetes Interventions and Complications (EDIC), Diabetes Care, 44, 2216, 10.2337/dc20-3097 · DOI
  4. Bartley, 2008, Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial, Diabet Med, 25, 442, 10.1111/j.1464-5491.2007.02407.x · DOI · Paper page
  5. Little, 2011, Hypoglycemia rates with basal insulin analogs, Diabetes Technol Ther, 13, S53, 10.1089/dia.2011.0022 · DOI
  6. Aronson, 2023, Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus, Diabetes Obes Metab, 25, 1964, 10.1111/dom.15063 · DOI · Paper page
  7. Heise, 2017, A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes, Clin Pharmacokinet, 56, 551, 10.1007/s40262-017-0514-8 · DOI · Paper page
  8. Bode, 2015, Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial, Diabetes Care, 38, 2266, 10.2337/dc15-0075 · DOI · Paper page
  9. Klaff, 2020, Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study, Diabetes Obes Metab, 22, 1799, 10.1111/dom.14100 · DOI
  10. Home, 2015, New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4), Diabetes Care, 38, 2217, 10.2337/dc15-0249 · DOI · Paper page
  11. Tzivian, 2022, Quantitative and qualitative analysis of the quality of life of type 1 diabetes patients using insulin pumps and of those receiving multiple daily insulin injections, Health Qual Life Outcomes, 20, 120, 10.1186/s12955-022-02029-2 · DOI
  12. Mulinacci, 2019, Glycemic outcomes with early initiation of continuous glucose monitoring system in recently diagnosed patients with type 1 diabetes, Diabetes Technol Ther, 21, 6, 10.1089/dia.2018.0257 · DOI · Paper page
  13. Elbalshy, 2022, Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials, Diabet Med, 39, e14854, 10.1111/dme.14854 · DOI · Paper page
  14. Champakanath, 2022, Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study, Diabetes Care, 45, 750, 10.2337/dc21-2004 · DOI · Paper page
  15. Peacock, 2023, A systematic review of commercial hybrid closed-loop automated insulin delivery systems, Diabetes Ther, 14, 839, 10.1007/s13300-023-01394-5 · DOI · Paper page
  16. Arunachalum, 2023, Glycemic outcomes during real-world hybrid closed-loop system use by individuals with type 1 diabetes in the United States, J Diabetes Sci Technol, 17, 951, 10.1177/19322968221088608 · DOI
  17. Garg, 2023, Improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial, Diabetes Technol Ther, 25, 1, 10.1089/dia.2022.0421 · DOI · Paper page
  18. Stahl-Pehe, 2025, Efficacy of automated insulin delivery systems in people with type 1 diabetes: a systematic review and network meta-analysis of outpatient randomised controlled trials, EClinicalMedicine, 82, 103190, 10.1016/j.eclinm.2025.103190 · DOI
  19. Burnside, 2023, Extended use of an open-source automated insulin delivery system in children and adults with type 1 diabetes: the 24-week continuation phase following the CREATE randomized controlled trial, Diabetes Technol Ther, 25, 250, 10.1089/dia.2022.0484 · DOI
  20. Lepore, 2022, Switching to the Minimed 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control, Acta Diabetol, 59, 1309, 10.1007/s00592-022-01937-5 · DOI
  21. Matejko, 2022, Transitioning of people with type 1 diabetes from multiple daily injections and self-monitoring of blood glucose directly to MiniMed 780G advanced hybrid closed-loop system: a two-center, randomized, controlled study, Diabetes Care, 45, 2628, 10.2337/dc22-0470 · DOI · Paper page
  22. Isganaitis, 2021, Closed-loop insulin therapy improves glycemic control in adolescents and young adults: outcomes from the international diabetes closed-loop trial, Diabetes Technol Ther, 23, 342, 10.1089/dia.2020.0572 · DOI · Paper page
  23. Forlenza, 2022, Real-world evidence supporting tandem control-IQ hybrid closed-loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations, Diabetes Technol Ther, 24, 814, 10.1089/dia.2022.0206 · DOI · Paper page
  24. Lal, 2019, Optimizing basal insulin dosing, J Pediatr, 215, 7, 10.1016/j.jpeds.2019.07.030 · DOI · Paper page
  25. Mitsui, 2022, Basal insulin requirement in patients with type 1 diabetes depends on the age and body mass index, J Diabetes Investig, 13, 292, 10.1111/jdi.13547 · DOI
  26. Castellano, 2018, The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen, J Diabetes Metab Disord, 17, 393, 10.1007/s40200-018-0358-2 · DOI
  27. Matejko, 2018, Basal insulin dose in adults with type 1 diabetes mellitus on insulin pumps in real-life clinical practice: a single-center experience, Adv Med, 2018, 1473160, 10.1155/2018/1473160 · DOI
  28. King, 2021, Mean basal insulin dose is 0.2 U/kg/d at near normal glycaemia for type 1 or 2 diabetes on continuous subcutaneous insulin infusion or once-nightly basal insulin, Diabetes Obesity Metabolism, 23, 866, 10.1111/dom.14265 · DOI
  29. Peters, 2013, The American Diabetes Association/JDRF Type 1 Diabetes Sourcebook.
  30. Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association, Diabetes Care, 37, 2034, 10.2337/dc14-1140 · DOI
  31. Sämann, 2006, Flexible intensive insulin therapy in adults with type 1 diabetes and high risk for severe hypoglycemia and diabetic ketoacidosis, Diabetes Care, 29, 2196, 10.2337/dc06-0751 · DOI
  32. Builes-Montaño, 2022, Efficacy and safety of carbohydrate counting versus other forms of dietary advice in patients with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised clinical trials, J Hum Nutr Diet, 35, 1030, 10.1111/jhn.13017 · DOI
  33. Al Balwi, 2022, Efficacy of insulin dosing algorithms for high-fat high-protein mixed meals to control postprandial glycemic excursions in people living with type 1 diabetes: a systematic review and meta-analysis, Pediatr Diabetes, 23, 1635, 10.1111/pedi.13436 · DOI · Paper page
  34. DAFNE Study Group, 2002, Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: Dose Adjustment For Normal Eating (DAFNE) randomised controlled trial, BMJ, 325, 746, 10.1136/bmj.325.7367.746 · DOI · Paper page
  35. Hopkins, 2012, Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience, Diabetes Care, 35, 1638, 10.2337/dc11-1579 · DOI · Paper page
  36. Speight, 2010, Long-term biomedical and psychosocial outcomes following DAFNE (Dose Adjustment For Normal Eating) structured education to promote intensive insulin therapy in adults with sub-optimally controlled type 1 diabetes, Diabetes Res Clin Pract, 89, 22, 10.1016/j.diabres.2010.03.017 · DOI · Paper page
  37. Bruttomesso, 2021, A “slide rule” to adjust insulin dose using trend arrows in adults with type 1 diabetes: test in silico and in real life, Diabetes Ther, 12, 1313, 10.1007/s13300-021-01020-2 · DOI
  38. Aleppo, 2017, A practical approach to using trend arrows on the Dexcom G5 CGM system for the management of adults with diabetes, J Endocr Soc, 1, 1445, 10.1210/js.2017-00388 · DOI
  39. Buckingham, 2008, Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator), Pediatr Diabetes, 9, 142, 10.1111/j.1399-5448.2007.00301.x · DOI
  40. Parise, 2023, A head-to-head comparison of two algorithms for adjusting mealtime insulin doses based on CGM trend arrows in adult patients with type 1 diabetes: results from an exploratory study, Int J Environ Res Public Health, 20, 10.3390/ijerph20053945 · DOI
  41. Petrovski, 2023, Simplified meal announcement versus precise carbohydrate counting in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed loop system: a randomized controlled trial comparing glucose control, Diabetes Care, 46, 544, 10.2337/dc22-1692 · DOI · Paper page
  42. Turrin, 2019, Effects of diabetes numeracy on glycemic control and diabetes self-management behaviors in patients on insulin pump therapy, Diabetes Ther, 10, 1337, 10.1007/s13300-019-0634-2 · DOI
  43. White, 2010, Addressing health literacy and numeracy to improve diabetes education and care, Diabetes Spectr, 23, 238, 10.2337/diaspect.23.4.238 · DOI
  44. Klonoff, 2025, Advance insulin injection technique and education with FITTER forward expert recommendations, Mayo Clin Proc, 100, 682, 10.1016/j.mayocp.2025.01.004 · DOI
  45. Bergenstal, 2015, Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes, Mayo Clin Proc, 90, 329, 10.1016/j.mayocp.2014.12.014 · DOI · Paper page
  46. Meng, 2018, Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials, Diabetes Metab Res Rev, 34, e2983, 10.1002/dmrr.2983 · DOI · Paper page
  47. Petrie, 2017, Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial, Lancet Diabetes Endocrinol, 5, 597, 10.1016/S2213-8587(17)30194-8 · DOI · Paper page
  48. von Herrath, 2021, Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Diabetes Endocrinol, 9, 212, 10.1016/S2213-8587(21)00019-X · DOI · Paper page
  49. Garg, 2024, Efficacy of semaglutide in overweight and obese patients with type 1 diabetes, Diabetes Technol Ther, 26, 184, 10.1089/dia.2023.0490 · DOI · Paper page
  50. Pasqua, 2025, Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial, Nat Med, 31, 1239, 10.1038/s41591-024-03463-z · DOI · Paper page
  51. Akturk, 2025, Efficacy and safety of tirzepatide in adults with type 1 diabetes: a proof of concept observational study, J Diabetes Sci Technol, 19, 292, 10.1177/19322968231223991 · DOI
  52. Rao, 2021, Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: meta-analysis of randomized controlled trials, Acta Diabetol, 58, 869, 10.1007/s00592-021-01686-x · DOI · Paper page
  53. Li, 2023, The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: a systematic review and meta-analysis, J Diabetes Complications, 37, 108632, 10.1016/j.jdiacomp.2023.108632 · DOI · Paper page
  54. Chen, 2020, Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: a systematic review and meta-analysis, Medicine (Baltimore), 99, e20875, 10.1097/MD.0000000000020875 · DOI · Paper page
  55. Bhatt, 2021, Sotagliflozin in patients with diabetes and chronic kidney disease, N Engl J Med, 384, 129, 10.1056/NEJMoa2030186 · DOI · Paper page
  56. Danne, 2019, International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors, Diabetes Care, 42, 1147, 10.2337/dc18-2316 · DOI · Paper page
  57. Lachin, 2014, Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial, Diabetes, 63, 739, 10.2337/db13-0881 · DOI · Paper page
  58. Kosheleva, 2025, Disease-modifying pharmacological treatments of type 1 diabetes: molecular mechanisms, target checkpoints, and possible combinatorial treatments, Pharmacol Rev, 77, 100044, 10.1016/j.pharmr.2025.100044 · DOI
  59. Dean, 2017, Pancreas transplantation, BMJ, 357, j1321, 10.1136/bmj.j1321 · DOI
  60. Geta, 2024, Effectiveness of shared decision-making for glycaemic control among type 2 diabetes mellitus adult patients: a systematic review and meta-analysis, PLoS One, 19, e0306296, 10.1371/journal.pone.0306296 · DOI · Paper page
  61. Lingvay, 2022, Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation, Lancet, 399, 394, 10.1016/S0140-6736(21)01919-X · DOI · Paper page
  62. Adler, 2024, Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91), Lancet, 404, 145, 10.1016/S0140-6736(24)00537-3 · DOI · Paper page
  63. Kunutsor, 2024, Glycaemic control and macrovascular and microvascular outcomes: a systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes, Diabetes Obes Metab, 26, 2069, 10.1111/dom.15511 · DOI
  64. Bahardoust, 2024, Effect of metformin (vs. placebo or sulfonylurea) on all-cause and cardiovascular mortality and incident cardiovascular events in patients with diabetes: an umbrella review of systematic reviews with meta-analysis, J Diabetes Metab Disord, 23, 27, 10.1007/s40200-023-01309-y · DOI · Paper page
  65. Maruthur, 2016, Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis, Ann Intern Med, 164, 740, 10.7326/M15-2650 · DOI · Paper page
  66. Salpeter, 2003, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis, Arch Intern Med, 163, 2594, 10.1001/archinte.163.21.2594 · DOI · Paper page
  67. Salpeter, 2010, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, Cochrane Database Syst Rev, 2010, CD002967
  68. Out, 2018, Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3year trial, J Diabetes Complications, 32, 171, 10.1016/j.jdiacomp.2017.11.001 · DOI · Paper page
  69. Sorli, 2017, Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial, Lancet Diabetes Endocrinol, 5, 251, 10.1016/S2213-8587(17)30013-X · DOI · Paper page
  70. Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med, 173, 278, 10.7326/M20-0864 · DOI · Paper page
  71. Buse, 2015, Is insulin the most effective injectable antihyperglycaemic therapy?, Diabetes Obes Metab, 17, 145, 10.1111/dom.12402 · DOI · Paper page
  72. D’Alessio, 2015, Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes, Diabetes Obes Metab, 17, 170, 10.1111/dom.12406 · DOI · Paper page
  73. Cahn, 2016, Clinical considerations for use of initial combination therapy in type 2 diabetes, Diabetes Care, 39(Suppl. 2), S137, 10.2337/dcS15-3007 · DOI
  74. Abdul-Ghani, 2015, Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial, Diabetes Obes Metab, 17, 268, 10.1111/dom.12417 · DOI · Paper page
  75. Cai, 2018, Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients: a systematic review and meta-analysis, Diabetes Ther, 9, 1995, 10.1007/s13300-018-0493-2 · DOI · Paper page
  76. Aroda, 2019, Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial, Lancet Diabetes Endocrinol, 7, 596, 10.1016/S2213-8587(19)30184-6 · DOI · Paper page
  77. Khunti, 2017, Clinical inertia-time to reappraise the terminology?, Prim Care Diabetes, 11, 105, 10.1016/j.pcd.2017.01.007 · DOI · Paper page
  78. Bennett, 2011, Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations, Ann Intern Med, 154, 602, 10.7326/0003-4819-154-9-201105030-00336 · DOI · Paper page
  79. Maloney, 2019, A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses, Clin Pharmacol Ther, 105, 1213, 10.1002/cpt.1307 · DOI · Paper page
  80. Lajthia, 2019, Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series, Pharm Pract (Granada), 17, 1588, 10.18549/PharmPract.2019.4.1588 · DOI · Paper page
  81. Violante, 2012, A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin, Diabet Med, 29, e417, 10.1111/j.1464-5491.2012.03624.x · DOI · Paper page
  82. Nauck, 2017, Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes, Diabetes Obes Metab, 19, 200, 10.1111/dom.12802 · DOI · Paper page
  83. Del Prato, 2021, Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial, Lancet, 398, 1811, 10.1016/S0140-6736(21)02188-7 · DOI · Paper page
  84. Abd El Aziz, 2017, A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients, Diabetes Obes Metab, 19, 216, 10.1111/dom.12804 · DOI · Paper page
  85. Aroda, 2017, Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial, Lancet Diabetes Endocrinol, 5, 355, 10.1016/S2213-8587(17)30085-2 · DOI · Paper page
  86. Davies, 2013, Once-weekly exenatide versus once- or twice-daily insulin detemir, Diabetes Care, 36, 1368, 10.2337/dc12-1333 · DOI · Paper page
  87. Diamant, 2010, Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial, Lancet, 375, 2234, 10.1016/S0140-6736(10)60406-0 · DOI · Paper page
  88. Kosiborod, 2024, Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials, Lancet, 404, 949, 10.1016/S0140-6736(24)01643-X · DOI
  89. McCoy, 2024, Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk, Nat Cardiovasc Res, 3, 431, 10.1038/s44161-024-00453-9 · DOI · Paper page
  90. Berg, 2019, Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus, Circulation, 140, 1569, 10.1161/CIRCULATIONAHA.119.042685 · DOI · Paper page
  91. McGuire, 2021, Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis, JAMA Cardiol, 6, 148, 10.1001/jamacardio.2020.4511 · DOI · Paper page
  92. Dagogo-Jack, 2021, Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial, BMJ Open Diabetes Res Care, 9, e002484, 10.1136/bmjdrc-2021-002484 · DOI · Paper page
  93. Cherney, 2018, Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin, Kidney Int, 93, 231, 10.1016/j.kint.2017.06.017 · DOI · Paper page
  94. Gastaldelli, 2022, Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial, Lancet Diabetes Endocrinol, 10, 393, 10.1016/S2213-8587(22)00070-5 · DOI · Paper page
  95. Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X · DOI · Paper page
  96. Abdul-Ghani, 2020, Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: a 3-year follow-up of the Qatar study, Diabetes Obes Metab, 22, 2287, 10.1111/dom.14153 · DOI · Paper page
  97. Lavynenko, 2022, Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT), Diabetes Obes Metab, 24, 899, 10.1111/dom.14650 · DOI · Paper page
  98. Garvey, 2023, Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 402, 613, 10.1016/S0140-6736(23)01200-X · DOI · Paper page
  99. Davies, 2021, Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial, Lancet, 397, 971, 10.1016/S0140-6736(21)00213-0 · DOI · Paper page
  100. Davies, 2015, Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial, JAMA, 314, 687, 10.1001/jama.2015.9676 · DOI · Paper page
  101. Ahmann, 2018, Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial, Diabetes Care, 41, 258, 10.2337/dc17-0417 · DOI · Paper page
  102. Blonde, 2009, Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study, Diabetes Obes Metab, 11, 623, 10.1111/j.1463-1326.2009.01060.x · DOI · Paper page
  103. Lucidi, 2021, Pharmacokinetic and pharmacodynamic head-to-head comparison of clinical, equivalent doses of insulin glargine 300 units · mL1 and insulin degludec 100 units·mL1 in type 1 diabetes, Diabetes Care, 44, 125, 10.2337/dc20-1033 · DOI
  104. Wang, 2010, Dose-response effects of insulin glargine in type 2 diabetes, Diabetes Care, 33, 1555, 10.2337/dc09-2011 · DOI · Paper page
  105. Semlitsch, 2020, (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus, Cochrane Database Syst Rev, 11, CD005613
  106. Mannucci, 2021, Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials, Endocrine, 74, 508, 10.1007/s12020-021-02889-6 · DOI · Paper page
  107. Mehta, 2021, Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care, Ann Med, 53, 998, 10.1080/07853890.2021.1925148 · DOI · Paper page
  108. Cowart, 2020, Overbasalization: addressing hesitancy in treatment intensification beyond basal insulin, Clin Diabetes, 38, 304, 10.2337/cd19-0061 · DOI
  109. Maiorino, 2019, The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials, Diabetes Res Clin Pract, 154, 101, 10.1016/j.diabres.2019.06.009 · DOI
  110. McCall, 2012, Insulin therapy and hypoglycemia, Endocrinol Metab Clin North Am, 41, 57, 10.1016/j.ecl.2012.03.001 · DOI · Paper page
  111. Fullerton, 2018, Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus, Cochrane Database Syst Rev, 12, CD013228
  112. de la Peña, 2011, Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects, Diabetes Care, 34, 2496, 10.2337/dc11-0721 · DOI · Paper page
  113. Hood, 2021, Treatment patterns and outcomes, before and after humulin R U-500 initiation, among high-dose type 2 diabetes mellitus patients in the United States, Endocr Pract, 27, 798, 10.1016/j.eprac.2021.05.006 · DOI · Paper page
  114. Becker, 2015, New insulin glargine 300 units · mL1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units · mL1, Diabetes Care, 38, 637, 10.2337/dc14-0006 · DOI · Paper page
  115. Riddle, 2015, One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension, Diabetes Obes Metab, 17, 835, 10.1111/dom.12472 · DOI · Paper page
  116. Yki-Järvinen, 2014, New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2), Diabetes Care, 37, 3235, 10.2337/dc14-0990 · DOI · Paper page
  117. de la Peña, 2016, Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog) 100 U/mL, Clin Pharmacol Drug Dev, 5, 69, 10.1002/cpdd.221 · DOI · Paper page
  118. Gentile, 2018, A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin u-100 versus concentrated lispro insulin u-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence, Expert Opin Drug Saf, 17, 445, 10.1080/14740338.2018.1453495 · DOI · Paper page
  119. Grant, 2022, Comparison of pharmacokinetics and pharmacodynamics of inhaled technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus, Clin Pharmacokinet, 61, 413, 10.1007/s40262-021-01084-0 · DOI · Paper page
  120. Akturk, 2018, Improved postprandial glucose with inhaled technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT study, Diabetes Technol Ther, 20, 639, 10.1089/dia.2018.0200 · DOI · Paper page
  121. Hoogwerf, 2021, Results of a 24-week trial of Technosphere insulin versus insulin aspart in type 2 diabetes, Endocr Pract, 27, 38, 10.1016/j.eprac.2020.11.002 · DOI · Paper page
  122. Martens, 2025, A randomized controlled trial using continuous glucose monitoring to guide food choices and diabetes self-care in people with type 2 diabetes not taking insulin, Diabetes Technol Ther, 27, 261, 10.1089/dia.2024.0579 · DOI
  123. Battelino, 2025, The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes, Diabetes Res Clin Pract, 223, 112111, 10.1016/j.diabres.2025.112111 · DOI
  124. Aronson, 2023, Impact of flash glucose monitoring in people with type 2 diabetes inadequately controlled with non-insulin antihyperglycaemic therapy (IMMEDIATE): a randomized controlled trial, Diabetes Obes Metab, 25, 1024, 10.1111/dom.14949 · DOI · Paper page
  125. Moon, 2023, Efficacy of intermittent short-term use of a real-time continuous glucose monitoring system in non-insulin-treated patients with type 2 diabetes: a randomized controlled trial, Diabetes Obes Metab, 25, 110, 10.1111/dom.14852 · DOI · Paper page
  126. Agarwal, 2025, Moving beyond glycated hemoglobin to glucose patterns: newer indications for continuous glucose monitor use, Endocr Pract, 31, 1046, 10.1016/j.eprac.2025.05.749 · DOI
  127. van Dijk, 2017, Hypoglycemia in frail elderly patients with type 2 diabetes mellitus treated with sulfonylurea, J Diabetes Sci Technol, 11, 438, 10.1177/1932296816668873 · DOI
  128. Hansen, 2022, The frequency of intermittently scanned glucose and diurnal variation of glycemic metrics, J Diabetes Sci Technol, 16, 1461, 10.1177/19322968211019382 · DOI · Paper page
  129. Urakami, 2022, Frequent scanning using flash glucose monitoring contributes to better glycemic control in children and adolescents with type 1 diabetes, J Diabetes Investig, 13, 185, 10.1111/jdi.13618 · DOI · Paper page
  130. Laffel, 2020, Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial, JAMA, 323, 2388, 10.1001/jama.2020.6940 · DOI · Paper page
  131. New, 2015, Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS), Diabet Med, 32, 609, 10.1111/dme.12713 · DOI
  132. Gubitosi-Klug, 2022, Continuous glucose monitoring in adults with type 1 diabetes with 35 years duration from the DCCT/EDIC study, Diabetes Care, 45, 659, 10.2337/dc21-0629 · DOI · Paper page
  133. Teo, 2022, Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis, Diabetologia, 65, 604, 10.1007/s00125-021-05648-4 · DOI · Paper page
  134. Seidu, Efficacy and safety of continuous glucose monitoring and intermittently scanned continuous glucose monitoring in patients with type 2 diabetes: a systematic review and meta-analysis of interventional evidence. Diabetes Care 2024;47:169-179, 10.2337/dci24-0023 · DOI
  135. Brown, 2020, Glycemic outcomes of use of CLC versus PLGS in type 1 diabetes: a randomized controlled trial, Diabetes Care, 43, 1822, 10.2337/dc20-0124 · DOI
  136. Pasquel, 2025, Automated insulin delivery in adults with type 2 diabetes: a nonrandomized clinical trial, JAMA Netw Open, 8, e2459348, 10.1001/jamanetworkopen.2024.59348 · DOI
  137. Bhargava, 2025, Safety and effectiveness of MiniMedTM 780G advanced hybrid closed-loop insulin intensification in adults with insulin-requiring type 2 diabetes, Diabetes Technol Ther, 27, 366, 10.1089/dia.2024.0586 · DOI
  138. Davis, 2023, Safety and efficacy of the Omnipod 5 automated insulin delivery system in adults with type 2 diabetes: from injections to hybrid closed-loop therapy, Diabetes Care, 46, 742, 10.2337/dc22-1915 · DOI · Paper page
  139. Kudva, 2025, A randomized trial of automated insulin delivery in type 2 diabetes, N Engl J Med, 392, 1801, 10.1056/NEJMoa2415948 · DOI · Paper page
  140. Valentine, 2019, Human factors usability and validation studies of a glucagon autoinjector in a simulated severe hypoglycemia rescue situation, Diabetes Technol Ther, 21, 522, 10.1089/dia.2019.0148 · DOI
  141. Settles, 2020, Nasal glucagon delivery is more successful than injectable delivery: a simulated severe hypoglycemia rescue, Endocr Pract, 26, 407, 10.4158/EP-2019-0502 · DOI
  142. Herges, 2023, Glucagon prescribing and costs among U.S. adults with diabetes, 2011-2021, Diabetes Care, 46, 620, 10.2337/dc22-1564 · DOI · Paper page
  143. Kahn, 2021, Glucagon use by U.S. adults with type 1 and type 2 diabetes, J Diabetes Complications, 35, 107882, 10.1016/j.jdiacomp.2021.107882 · DOI · Paper page
  144. Kang, 2018, Cost-related medication non-adherence among U.S. adults with diabetes, Diabetes Res Clin Pract, 143, 24, 10.1016/j.diabres.2018.06.016 · DOI · Paper page
  145. Baig KA, Fry CE, Buntin MB, Powers AC, Dusetzina SB . Insulin out-of-pocket spending caps and employer-sponsored insurance: changes in out-of-pocket and total costs for insulin and healthcare. Health Serv Res 2025:e14656 · DOI
  146. Suran, 2023, All 3 major insulin manufacturers are cutting their prices-here’s what the news means for patients with diabetes, JAMA, 329, 1337, 10.1001/jama.2022.11688 · DOI · Paper page
  147. Herges, 2021, Easing the financial burden of diabetes management: a guide for patients and primary care clinicians, Clin Diabetes, 39, 427, 10.2337/cd21-0004 · DOI
  148. Lambson, 2023, Administration errors of compounded semaglutide reported to a poison control center-case series, J Am Pharm Assoc (2003), 63, 1643, 10.1016/j.japh.2023.06.017 · DOI · Paper page
  149. Skelley, 2024, The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception, J Am Pharm Assoc (2003), 64, 204, 10.1016/j.japh.2023.10.037 · DOI
  150. Chang, 2019, Endocrine toxicity of cancer immunotherapy targeting immune checkpoints, Endocr Rev, 40, 17, 10.1210/er.2018-00006 · DOI
  151. Zhou, 2024, A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis, Front Immunol, 15, 1448728, 10.3389/fimmu.2024.1448728 · DOI
  152. Liu, 2020, Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015–2019, Diabetes Care, 43, e79, 10.2337/dc20-0459 · DOI · Paper page
  153. Mulla, 2023, Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment, Diabet Med, 40, e15053, 10.1111/dme.15053 · DOI
  154. Byun, 2020, Immune checkpoint inhibitor-associated diabetes: a single-institution experience, Diabetes Care, 43, 3106, 10.2337/dc20-0609 · DOI · Paper page
  155. Schneider, 2021, Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update, J Clin Oncol, 39, 4073, 10.1200/JCO.21.01440 · DOI
  156. Goncalves, 2018, phosphatidylinositol 3-kinase, growth disorders, and cancer, N Engl J Med, 379, 2052, 10.1056/NEJMra1704560 · DOI · Paper page
  157. Rugo, 2020, Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer, Ann Oncol, 31, 1001, 10.1016/j.annonc.2020.05.001 · DOI · Paper page
  158. Jhaveri, 2025, Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer, N Engl J Med, 393, 151, 10.1056/NEJMoa2501796 · DOI
  159. Liu, 2022, Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment, Cancer Med, 11, 1796, 10.1002/cam4.4579 · DOI
  160. Gallagher, 2024, Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique, NPJ Breast Cancer, 10, 12, 10.1038/s41523-024-00613-x · DOI · Paper page
  161. Ihle, 2009, Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity, Mol Cancer Ther, 8, 94, 10.1158/1535-7163.MCT-08-0714 · DOI
  162. Borrego, 2024, SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials, Breast Cancer Res Treat, 208, 111, 10.1007/s10549-024-07405-8 · DOI
  163. Goncalves, 2022, Management of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia, Integr Cancer Ther, 21, 15347354211073163, 10.1177/15347354211073163 · DOI · Paper page
  164. Khan, 2016, Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase b/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management, Oncologist, 21, 855, 10.1634/theoncologist.2015-0248 · DOI
  165. Busaidy, 2012, Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway, J Clin Oncol, 30, 2919, 10.1200/JCO.2011.39.7356 · DOI
  166. Nowak, 2021, High prevalence of steroid-induced glucose intolerance with normal fasting glycaemia during low-dose glucocorticoid therapy: an oral glucose tolerance test screening study, Rheumatology (Oxford), 60, 2842, 10.1093/rheumatology/keaa724 · DOI
  167. Kulkarni, 2022, Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis, BMJ Open, 12, e061476, 10.1136/bmjopen-2022-061476 · DOI
  168. Perez, 2014, Glucocorticoid-induced hyperglycemia, J Diabetes, 6, 9, 10.1111/1753-0407.12090 · DOI
  169. Elena, 2018, Hyperglycemia and diabetes induced by glucocorticoids in nondiabetic and diabetic patients: revision of literature and personal considerations, Curr Pharm Biotechnol, 19, 1210, 10.2174/1389201020666190102145305 · DOI
  170. Zhang, 2021, Glycemic profile of intravenous dexamethasone-induced hyperglycemia using continuous glucose monitoring, Am J Case Rep, 22, e930733, 10.12659/AJCR.930733 · DOI
  171. Wallace, 2018, Optimizing the treatment of steroid-induced hyperglycemia, Ann Pharmacother, 52, 86, 10.1177/1060028017728297 · DOI
  172. Limbachia, 2024, The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hospitalized inpatients with and without diabetes, Clin Ther, 46, e59, 10.1016/j.clinthera.2023.11.013 · DOI
  173. Limbachia, 2024, Differential effects of oral versus intravenous hydrocortisone and dexamethasone on capillary blood glucose levels in adult inpatients - a single centre study, Clin Med (Lond), 24, 100249, 10.1016/j.clinme.2024.100249 · DOI
  174. Gerards, 2016, Add-on treatment with intermediate-acting insulin versus sliding-scale insulin for patients with type 2 diabetes or insulin resistance during cyclic glucocorticoid-containing antineoplastic chemotherapy: a randomized crossover study, Diabetes Obes Metab, 18, 1041, 10.1111/dom.12694 · DOI · Paper page
  175. Burt, 2015, Efficacy of a basal bolus insulin protocol to treat prednisolone-induced hyperglycaemia in hospitalised patients, Intern Med J, 45, 261, 10.1111/imj.12680 · DOI · Paper page
  176. Türk, 2006, Repaglinide in the management of new-onset diabetes mellitus after renal transplantation, Am J Transplant, 6, 842, 10.1111/j.1600-6143.2006.01250.x · DOI
  177. Ode, 2022, ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents, Pediatr Diabetes, 23, 1212, 10.1111/pedi.13453 · DOI · Paper page
  178. Kurnikowski, 2022, Criteria for prediabetes and posttransplant diabetes mellitus after kidney transplantation: a 2-year diagnostic accuracy study of participants from a randomized controlled trial, Am J Transplant, 22, 2880, 10.1111/ajt.17187 · DOI
  179. Sharif, 2024, International consensus on post-transplantation diabetes mellitus, Nephrol Dial Transplant, 39, 531, 10.1093/ndt/gfad258 · DOI
  180. Kuningas, 2020, Comparing glycaemic benefits of active versus passive lifestyle intervention in kidney allograft recipients: a randomized controlled trial, Transplantation, 104, 1491, 10.1097/TP.0000000000002969 · DOI
  181. Hecking, 2012, Early basal insulin therapy decreases new-onset diabetes after renal transplantation, J Am Soc Nephrol, 23, 739, 10.1681/ASN.2011080835 · DOI
  182. Schwaiger, 2021, Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation: a multicenter randomized trial, J Am Soc Nephrol, 32, 2083, 10.1681/ASN.2021010127 · DOI
  183. Chandra, 2023, Hypoglycemia with insulin in post-transplant diabetes mellitus, Transpl Immunol, 78, 101833, 10.1016/j.trim.2023.101833 · DOI
  184. Tuerk, 2008, Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation, Clin Nephrol, 70, 26, 10.5414/CNP70026 · DOI
  185. Lo, 2020, Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients, Cochrane Database Syst Rev, 8, CD009966
  186. Lawrence, 2023, Sweet and simple as syrup: a review and guidance for use of novel antihyperglycemic agents for post-transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation, Clin Transplant, 37, e14922, 10.1111/ctr.14922 · DOI
  187. Munoz Pena, 2023, Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia, J Clin Endocrinol Metab, 109, e1, 10.1210/clinem/dgad395 · DOI · Paper page
  188. Ram, 2019, Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation, Cardiovasc Diabetol, 18, 118, 10.1186/s12933-019-0925-y · DOI · Paper page
  189. Vest, 2018, Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: a retrospective analysis of integrated registry and pharmacy claims data, Clin Transplant, 32, e13302, 10.1111/ctr.13302 · DOI · Paper page
  190. Abdelaziz, 2020, Efficacy and safety of dipeptidyl peptidase-4 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus (PTDM)- a systematic review and meta-analysis, Curr Diabetes Rev, 16, 580, 10.2174/1573399815666190321144310 · DOI
  191. Thangavelu, 2020, A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation, Diabetes Ther, 11, 987, 10.1007/s13300-020-00786-1 · DOI · Paper page
  192. Kukla, 2020, The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients, Transplant Direct, 6, e524, 10.1097/TXD.0000000000000971 · DOI · Paper page
  193. Singh, 2019, Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients, Diabetes Obes Metab, 21, 1061, 10.1111/dom.13619 · DOI · Paper page
  194. Liou, 2018, Management of diabetes mellitus with glucagonlike peptide-1 agonist liraglutide in renal transplant recipients: a retrospective study, Transplant Proc, 50, 2502, 10.1016/j.transproceed.2018.03.087 · DOI
  195. Vigara, 2022, Effectiveness and safety of glucagon-like peptide-1 receptor agonist in a cohort of kidney transplant recipients, Clin Transplant, 36, e14633, 10.1111/ctr.14633 · DOI
  196. Sweiss, 2022, Single-center evaluation of safety & efficacy of glucagon-like peptide-1 receptor agonists in solid organ transplantation, Prog Transplant, 32, 357, 10.1177/15269248221122867 · DOI
  197. Zelada, 2025, Efficacy, tolerability, and safety of glucagon-like peptide 1 receptor agonists (GLP1-RA) in kidney transplant recipients with diabetes, Clin Transplant, 39, e70144, 10.1111/ctr.70144 · DOI
  198. Kim, 2021, Dulaglutide as an effective replacement for prandial insulin in kidney transplant recipients with type 2 diabetes mellitus: a retrospective review, Diabetes Metab J, 45, 948, 10.4093/dmj.2020.0180 · DOI
  199. Orandi, 2025, GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study, Lancet Diabetes Endocrinol, 13, 374, 10.1016/S2213-8587(24)00371-1 · DOI
  200. Lin, 2025, Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients, Cardiovasc Diabetol, 24, 87, 10.1186/s12933-025-02649-0 · DOI

200 of 213 shown

Cited by

Sorted by citations

Metadata

Authors
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., Everett, B. M., Garg, R., Laffel, L. M., Lal, R., Matfin, G., Nelson, A. B., Neumiller, J. J., Pandya, N., Pekas, E. J., Peters, A. L., Pilla, S. J., Romeo, G. R., Rosas, S. E., Sadhu, A. R., Segal, A. R., Simmons, K. M., Szmuilowicz, E. D., & ElSayed, N. A.
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2025-12-08
Volume
49
Issue
Supplement_1
Pages
S183-S215
ISSN
  • 0149-5992
  • 1935-5548
DOI
10.2337/dc26-s009
Cited by
263
References
86
Language
en
Licence
www.diabetesjournals.org/content/license (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review